111 related articles for article (PubMed ID: 14988411)
1. Site-directed targeting of plasminogen activator inhibitor-1 as an example for a novel approach in rational drug design.
De Taeye B; Compernolle G; Declerck PJ
J Biol Chem; 2004 May; 279(19):20447-50. PubMed ID: 14988411
[TBL] [Abstract][Full Text] [Related]
2. Elucidation of a novel epitope of a substrate-inducing monoclonal antibody against the serpin PAI-1.
Naessens D; Gils A; Compernolle G; Declerck PJ
J Thromb Haemost; 2003 May; 1(5):1028-33. PubMed ID: 12871373
[TBL] [Abstract][Full Text] [Related]
3. Additivity in effects of vitronectin and monoclonal antibodies against alpha-helix F of plasminogen activator inhibitor-1 on its reactions with target proteinases.
Komissarov AA; Andreasen PA; Bødker JS; Declerck PJ; Anagli JY; Shore JD
J Biol Chem; 2005 Jan; 280(2):1482-9. PubMed ID: 15516335
[TBL] [Abstract][Full Text] [Related]
4. The distal hinge of the reactive site loop and its proximity: a target to modulate plasminogen activator inhibitor-1 activity.
Bijnens AP; Gils A; Stassen JM; Komissarov AA; Knockaert I; Brouwers E; Shore JD; Declerck PJ
J Biol Chem; 2001 Nov; 276(48):44912-8. PubMed ID: 11559698
[TBL] [Abstract][Full Text] [Related]
5. Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis.
Björquist P; Ehnebom J; Inghardt T; Hansson L; Lindberg M; Linschoten M; Strömqvist M; Deinum J
Biochemistry; 1998 Feb; 37(5):1227-34. PubMed ID: 9477948
[TBL] [Abstract][Full Text] [Related]
6. Epitope mapping for four monoclonal antibodies against human plasminogen activator inhibitor type-1: implications for antibody-mediated PAI-1-neutralization and vitronectin-binding.
Wind T; Jensen MA; Andreasen PA
Eur J Biochem; 2001 Feb; 268(4):1095-106. PubMed ID: 11179976
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of conversion of plasminogen activator inhibitor 1 from a suicide inhibitor to a substrate by monoclonal antibodies.
Komissarov AA; Declerck PJ; Shore JD
J Biol Chem; 2002 Nov; 277(46):43858-65. PubMed ID: 12223472
[TBL] [Abstract][Full Text] [Related]
8. Identification of a functional epitope in plasminogen activator inhibitor-1, not localized in the reactive center loop.
Debrock S; Declerck PJ
Thromb Haemost; 1998 Mar; 79(3):597-601. PubMed ID: 9531048
[TBL] [Abstract][Full Text] [Related]
9. A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis.
Chorostowska-Wynimko J; Swiercz R; Skrzypczak-Jankun E; Wojtowicz A; Selman SH; Jankun J
Mol Cancer Ther; 2003 Jan; 2(1):19-28. PubMed ID: 12533669
[TBL] [Abstract][Full Text] [Related]
10. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms.
Debrock S; Declerck PJ
Biochim Biophys Acta; 1997 Feb; 1337(2):257-66. PubMed ID: 9048903
[TBL] [Abstract][Full Text] [Related]
11. Time-resolved polarized fluorescence spectroscopy studies of plasminogen activator inhibitor type 1: conformational changes of the reactive center upon interactions with target proteases, vitronectin and heparin.
Fa M; Karolin J; Aleshkov S; Strandberg L; Johansson LB; Ny T
Biochemistry; 1995 Oct; 34(42):13833-40. PubMed ID: 7577977
[TBL] [Abstract][Full Text] [Related]
12. Function-stabilizing mechanism of plasminogen activator inhibitor type 1 induced upon binding to alpha1-acid glycoprotein.
Smolarczyk K; Gils A; Boncela J; Declerck PJ; Cierniewski CS
Biochemistry; 2005 Sep; 44(37):12384-90. PubMed ID: 16156651
[TBL] [Abstract][Full Text] [Related]
13. Importance of N-terminal residues in plasminogen activator inhibitor 1 on its antibody induced latency transition.
Ngo TH; Zhou Y; Stassen JM; Declerck PJ
Thromb Haemost; 2002 Aug; 88(2):288-93. PubMed ID: 12195702
[TBL] [Abstract][Full Text] [Related]
14. Elucidation of the binding regions of PAI-1 neutralizing antibodies using chimeric variants of human and rat PAI-1.
Bijnens AP; Ngo TH; Gils A; Dewaele J; Knockaert I; Stassen JM; Declerck PJ
Thromb Haemost; 2001 May; 85(5):866-74. PubMed ID: 11372681
[TBL] [Abstract][Full Text] [Related]
15. Elucidation of the paratope of scFv-8H9D4, a PAI-1 neutralizing antibody derivative.
Verbeke K; Gils A; Stassen JM; Declerck PJ
Thromb Haemost; 2003 Jan; 89(1):74-82. PubMed ID: 12540956
[TBL] [Abstract][Full Text] [Related]
16. Elucidation of the epitope of a latency-inducing antibody: identification of a new molecular target for PAI-1 inhibition.
Naessens D; Gils A; Compernolle G; Declerck PJ
Thromb Haemost; 2003 Jul; 90(1):52-8. PubMed ID: 12876625
[TBL] [Abstract][Full Text] [Related]
17. Importance of the hinge region between alpha-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodies.
Bijnens AP; Gils A; Knockaert I; Stassen JM; Declerck PJ
J Biol Chem; 2000 Mar; 275(9):6375-80. PubMed ID: 10692438
[TBL] [Abstract][Full Text] [Related]
18. Mapping of the epitope of a monoclonal antibody protecting plasminogen activator inhibitor-1 against inactivating agents.
Bødker JS; Wind T; Jensen JK; Hansen M; Pedersen KE; Andreasen PA
Eur J Biochem; 2003 Apr; 270(8):1672-9. PubMed ID: 12694180
[TBL] [Abstract][Full Text] [Related]
19. A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state.
Mathiasen L; Dupont DM; Christensen A; Blouse GE; Jensen JK; Gils A; Declerck PJ; Wind T; Andreasen PA
Mol Pharmacol; 2008 Sep; 74(3):641-53. PubMed ID: 18559377
[TBL] [Abstract][Full Text] [Related]
20. High-density mutagenesis by combined DNA shuffling and phage display to assign essential amino acid residues in protein-protein interactions: application to study structure-function of plasminogen activation inhibitor 1 (PAI-I).
Stoop AA; Jespers L; Lasters I; Eldering E; Pannekoek H
J Mol Biol; 2000 Sep; 301(5):1135-47. PubMed ID: 10966811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
